STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

SGHT insider Jeremy Hayden exercises options, reports 3,150-share sale

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Sight Sciences, Inc. (SGHT)11/12/2025, he exercised stock options for 2,440 shares of common stock at $1.96 per share and an additional 710 shares at the same exercise price, all under the company’s equity incentive plan.

The same day, 3,150 shares of common stock were sold at a weighted average price of $8.01 per share, in multiple trades between $8.00 and $8.06. Following these transactions, Hayden beneficially owned 256,590 shares of common stock directly. The filing states the transactions were made under a Rule 10b5-1 trading plan tied to a marital separation agreement, and that his former spouse will receive all proceeds from the share sales.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HAYDEN JEREMY B.

(Last) (First) (Middle)
C/O SIGHT SCIENCES, INC.
4040 CAMPBELL AVE., SUITE 100

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/12/2025 M(1) 2,440(2) A $1.96 259,030 D
Common Stock 11/12/2025 M(1) 710(2) A $1.96 259,740 D
Common Stock 11/12/2025 S(1) 3,150 D $8.01(3) 256,590 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.96 11/12/2025 M(1) 2,440 (4) 05/10/2030 Common Stock 2,440 $0 0 D
Stock Option (Right to Buy) $1.96 11/12/2025 M(1) 710 (4) 07/28/2030 Common Stock 710 $0 0 D
Explanation of Responses:
1. The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with, and pursuant to, the terms of a marital separation agreement previously entered into between the Reporting Person and his former spouse. The Reporting Person's spouse will receive all proceeds from the shares sold in the transactions.
2. Reflects the exercise of stock options awarded to the Reporting Person under the Issuer's equity incentive plan.
3. Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The options are fully vested and exercisable.
Jeremy Hayden 11/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the latest Form 4 for Sight Sciences (SGHT) report?

The Form 4 reports that Chief Legal Officer Jeremy Hayden exercised stock options for a total of 3,150 shares of Sight Sciences common stock at an exercise price of $1.96 per share and sold 3,150 shares on 11/12/2025.

How many Sight Sciences (SGHT) shares did Jeremy Hayden sell and at what price?

Jeremy Hayden sold 3,150 shares of Sight Sciences common stock at a weighted average price of $8.01 per share, with individual trades executed between $8.00 and $8.06.

How many Sight Sciences (SGHT) shares does Jeremy Hayden own after these transactions?

After the reported transactions, Jeremy Hayden beneficially owned 256,590 shares of Sight Sciences common stock directly.

Were the SGHT trades by Jeremy Hayden under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Jeremy Hayden.

Who receives the proceeds from the Sight Sciences (SGHT) share sales reported in this Form 4?

The filing explains that, under a marital separation agreement, Jeremy Hayden’s former spouse will receive all proceeds from the shares sold.

What stock options did Jeremy Hayden exercise in this SGHT Form 4?

He exercised fully vested stock options for 2,440 shares with an expiration date of 05/10/2030 and 710 shares with an expiration date of 07/28/2030, each at an exercise price of $1.96 per share.
Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Latest News

SGHT Latest SEC Filings

SGHT Stock Data

431.96M
41.82M
20.66%
50.37%
1.99%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MENLO PARK